These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 27699930)

  • 1. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis.
    Mellergård J; Tisell A; Blystad I; Grönqvist A; Blennow K; Olsson B; Dahle C; Vrethem M; Lundberg P; Ernerudh J
    Eur J Neurol; 2017 Jan; 24(1):112-121. PubMed ID: 27699930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain Atrophy in Natalizumab-treated Patients with Multiple Sclerosis: A 5-year Retrospective Study.
    Eisele P; Szabo K; Ebert A; Platten M; Gass A
    J Neuroimaging; 2019 Mar; 29(2):190-192. PubMed ID: 30485572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
    Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
    J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between change in normal appearing white matter metabolites and intrathecal inflammation in natalizumab-treated multiple sclerosis.
    Mellergård J; Tisell A; Dahlqvist Leinhard O; Blystad I; Landtblom AM; Blennow K; Olsson B; Dahle C; Ernerudh J; Lundberg P; Vrethem M
    PLoS One; 2012; 7(9):e44739. PubMed ID: 23028598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
    Zivadinov R; Hojnacki D; Bergsland N; Kennedy C; Hagemeier J; Melia R; Ramasamy DP; Durfee J; Carl E; Dwyer MG; Weinstock-Guttman B
    Eur J Neurol; 2016 Jun; 23(6):1101-9. PubMed ID: 26998905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
    Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
    Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between inflammatory activity and brain atrophy in natalizumab treated patients.
    Magraner M; Coret F; Casanova B
    Eur J Radiol; 2012 Nov; 81(11):3485-90. PubMed ID: 22391507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.
    Constantinescu R; Krýsl D; Bergquist F; Andrén K; Malmeström C; Asztély F; Axelsson M; Menachem EB; Blennow K; Rosengren L; Zetterberg H
    Eur J Neurol; 2016 Apr; 23(4):796-806. PubMed ID: 26822123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.
    Villar LM; Picón C; Costa-Frossard L; Alenda R; García-Caldentey J; Espiño M; Muriel A; Álvarez-Cermeño JC
    Eur J Neurol; 2015 Aug; 22(8):1169-75. PubMed ID: 25324032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
    Ciampi E; Pareto D; Sastre-Garriga J; Vidal-Jordana A; Tur C; Río J; Tintoré M; Auger C; Rovira A; Montalban X
    Mult Scler; 2017 Apr; 23(4):556-566. PubMed ID: 27354019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults.
    Idland AV; Sala-Llonch R; Borza T; Watne LO; Wyller TB; Brækhus A; Zetterberg H; Blennow K; Walhovd KB; Fjell AM
    Neurobiol Aging; 2017 Jan; 49():138-144. PubMed ID: 27794264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls.
    Alvarez E; Nair KV; Hoyt BD; Seale RA; Sillau S; Miravalle A; Engebretson E; Schurr B; Corboy JR; Vollmer TL; Honce JM
    Mult Scler Relat Disord; 2021 Oct; 55():103170. PubMed ID: 34364034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
    Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
    Mult Scler; 2017 Jan; 23(1):62-71. PubMed ID: 27003946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of CSF NfL and tau in ALS.
    Schreiber S; Spotorno N; Schreiber F; Acosta-Cabronero J; Kaufmann J; Machts J; Debska-Vielhaber G; Garz C; Bittner D; Hensiek N; Dengler R; Petri S; Nestor PJ; Vielhaber S
    J Neurol; 2018 Nov; 265(11):2633-2645. PubMed ID: 30187162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.
    Koskimäki F; Bernard J; Yong J; Arndt N; Carroll T; Lee SK; Reder AT; Javed A
    PLoS One; 2018; 13(12):e0209326. PubMed ID: 30576361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
    Romme Christensen J; Komori M; von Essen MR; Ratzer R; Börnsen L; Bielekova B; Sellebjerg F
    Mult Scler; 2019 Jun; 25(7):937-946. PubMed ID: 29775134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced axonal metabolism during early natalizumab treatment in relapsing-remitting multiple sclerosis.
    Wiebenga OT; Klauser AM; Schoonheim MM; Nagtegaal GJ; Steenwijk MD; van Rossum JA; Polman CH; Barkhof F; Pouwels PJ; Geurts JJ
    AJNR Am J Neuroradiol; 2015 Jun; 36(6):1116-23. PubMed ID: 25742985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
    Sastre-Garriga J; Tur C; Pareto D; Vidal-Jordana A; Auger C; Río J; Huerga E; Tintoré M; Rovira A; Montalban X
    Mult Scler; 2015 May; 21(6):749-56. PubMed ID: 25392330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.